[go: up one dir, main page]

JP5177728B2 - NK cell activator - Google Patents

NK cell activator Download PDF

Info

Publication number
JP5177728B2
JP5177728B2 JP2004203601A JP2004203601A JP5177728B2 JP 5177728 B2 JP5177728 B2 JP 5177728B2 JP 2004203601 A JP2004203601 A JP 2004203601A JP 2004203601 A JP2004203601 A JP 2004203601A JP 5177728 B2 JP5177728 B2 JP 5177728B2
Authority
JP
Japan
Prior art keywords
polysaccharide
fermented milk
cells
acidic
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004203601A
Other languages
Japanese (ja)
Other versions
JP2005194259A (en
Inventor
聖也 牧野
秀二 池上
紀宏 指原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Co Ltd
Original Assignee
Meiji Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Co Ltd filed Critical Meiji Co Ltd
Priority to JP2004203601A priority Critical patent/JP5177728B2/en
Publication of JP2005194259A publication Critical patent/JP2005194259A/en
Application granted granted Critical
Publication of JP5177728B2 publication Critical patent/JP5177728B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Description

本発明は、ナチュラルキラー(以下「NK」ともいう)細胞活性化作用を有する組成物に関するものである。   The present invention relates to a composition having a natural killer (hereinafter also referred to as “NK”) cell activation effect.

NK細胞は、名前のとおりウイルス感染細胞やがん細胞をいち早く発見して殺す働きがあり、インフルエンザなどの感染症予防、癌予防の決め手として注目されている。しかしながらNK細胞の活性(破壊能力)は加齢とともに低下し、高齢になるほどガン発生率が高くなるのは、NK細胞の活性化の衰えに関連しているとされている。また、NK細胞は自律神経に影響を受けるため、ストレスを受けて交感神経が優位になるとNK細胞の活性(破壊能力)は激減する。このように、健康を維持するためには、NK細胞の活性化が不可欠である。そして、NK細胞活性化を促進する物質が探索されているが、薬剤として利用されるものがほとんどである。食品として利用可能な素材としては、多糖(レンチナン、キチン、キトサン、マイタケD-フラクション、ニゲロオリゴ糖等)および菌体(Lactobacillus casei shirota、Bifidobacterium lactis HN019等)が知られている(非特許文献1〜6、特許文献1)が、必ずしも十分な活性を得ることが出来なかった。しかしながら、食品として利用されている素材由来であれば、日常生活において安全かつ簡便に摂取し、免疫力の増強が期待される。
秋山由紀雄, 羽室淳爾, 蛋白質 核酸 酵素, 26(3), 208-224(1981) Nishimura K, Nishimura S, Nishi N, Numata F, Tone Y, Tokura S, Azuma I, Vaccine,3(5),379-84(1985) Kodama N, Komuta K, Sakai N, Nanba H, Biol Pharm Bull,25(12),1647-50(2002) Murosak S, Muroyama K, Yamamoto Y, Liu T, Yoshikai Y,Int Immunopharmacol,2(1),151-9(2002) Hori T, Kiyoshima J, Yasui H, Biosci Biotechnol Biochem,67(2),420-2(2003) Gill HS, Rutherfurd KJ, Cross ML, Gopal PK., Am J Clin Nutr,74(6),833-9(2001) 特開2001-31573号公報
As the name suggests, NK cells have the ability to quickly detect and kill virus-infected cells and cancer cells, and are attracting attention as a deciding factor in preventing influenza and other infectious diseases. However, the activity (destructive capacity) of NK cells decreases with aging, and the higher the incidence of cancer with increasing age, it is said to be related to the decline in activation of NK cells. In addition, since NK cells are affected by autonomic nerves, when sympathetic nerves become dominant under stress, NK cell activity (destructive ability) decreases drastically. Thus, in order to maintain health, activation of NK cells is indispensable. And although the substance which promotes NK cell activation is searched, most are utilized as a chemical | medical agent. As materials that can be used as food, polysaccharides (lentinan, chitin, chitosan, maitake D-fraction, nigerooligosaccharide, etc.) and bacterial cells (Lactobacillus casei shirota, Bifidobacterium lactis HN019, etc.) are known (Non-Patent Documents 1 to 4). 6, Patent Document 1) cannot always obtain sufficient activity. However, if it is derived from a material used as a food, it is expected to be safely and easily ingested in daily life and enhance immunity.
Yukio Akiyama, Jun Hamuro, Protein Nucleic Acid Enzyme, 26 (3), 208-224 (1981) Nishimura K, Nishimura S, Nishi N, Numata F, Tone Y, Tokura S, Azuma I, Vaccine, 3 (5), 379-84 (1985) Kodama N, Komuta K, Sakai N, Nanba H, Biol Pharm Bull, 25 (12), 1647-50 (2002) Murosak S, Muroyama K, Yamamoto Y, Liu T, Yoshikai Y, Int Immunopharmacol, 2 (1), 151-9 (2002) Hori T, Kiyoshima J, Yasui H, Biosci Biotechnol Biochem, 67 (2), 420-2 (2003) Gill HS, Rutherfurd KJ, Cross ML, Gopal PK., Am J Clin Nutr, 74 (6), 833-9 (2001) JP 2001-31573 A

そこで、NK細胞を活性化し、免疫力を高める食品由来の組成物が望まれている。   Therefore, a food-derived composition that activates NK cells and enhances immunity is desired.

本発明者らは、NK細胞を活性化する食品由来の組成物を検討したところ、酸性多糖類にNK細胞活性化作用があることを見出して本発明を完成させた。
本発明は、具体的には、
[1] 酸性多糖類を有効成分として含有することを特徴とするNK細胞活性化剤、
[2] 酸性多糖類がリン酸化多糖類である上記[1]記載のNK細胞活性化剤、
[3] 多糖類が乳酸菌由来である上記[1]または[2]記載のNK細胞活性化剤、
[4] 上記[1]〜[3]のいずれか1つに記載のNK細胞活性化剤を含み、NK細胞活性化作用を有するものであることを特徴とし、NK細胞活性化のために用いられる旨の表示を付した発酵乳、
を提供するものである。
When the present inventors examined the composition derived from the foodstuff which activates NK cell, it discovered that acidic polysaccharide had NK cell activation effect | action, and completed this invention.
The present invention specifically includes:
[1] An NK cell activator comprising an acidic polysaccharide as an active ingredient,
[2] The NK cell activator according to [1] above, wherein the acidic polysaccharide is a phosphorylated polysaccharide,
[3] The NK cell activator according to [1] or [2] above, wherein the polysaccharide is derived from lactic acid bacteria,
[4] The NK cell activator according to any one of [1] to [3] above, which has an NK cell activation action, and is used for NK cell activation Fermented milk with an indication that
Is to provide.

酸性多糖類からなるNK細胞活性化剤により、インフルエンザなどの感染予防、癌の予防、進行の防止などが可能となった。根本治療法のないこれらの疾患の治療または予防薬の一つを新たに提供することができる。   An NK cell activator comprising an acidic polysaccharide has made it possible to prevent infection such as influenza, prevent cancer, and prevent progression. One of the therapeutic or prophylactic drugs for these diseases without a fundamental treatment can be newly provided.

本発明のNK細胞活性化剤は、酸性多糖類、好ましくはリン酸化多糖類を有効成分とする。リン酸化多糖類には、多糖類を産生する乳酸菌の培養物、該培養物から精製した多糖類、多糖類を化学的又は酵素的にリン酸化して得られた多糖類などが挙げられる。リン酸化多糖類中のリン含有量は0.01%以上であることが好ましく、0.1%以上であることがさらに好ましい。また、本願発明でいう多糖類には、当該多糖を化学的又は酵素的に分解して得られたオリゴ糖を含む。
本発明に用いられる乳酸菌としては、多糖類を生産する乳酸菌であれば、種類を問わない。酸性多糖類は単独で、または種類の異なる2種以上を組み合わせて用いてもよい。
乳酸菌としては、ラクトバチルス・ブルガリクス(Lactobacillus bulgaricus)、またはラクトコッカス・ラクティス・クレモリス(Lactococcus lactis ssp. cremoris) 等が、単独でまたは組み合わせて用いられる。これらの中でもLactococcus lactis ssp. cremoris KVS20株(Kitazawa H, Yamaguchi T, Miura M, Saito T, Itoh T, J Dairy Sci,76,1514-9(1993)), Lactobacillus bulgaricusOLL1073R-1株(FERM P-17227)が好適である。
The NK cell activator of the present invention contains an acidic polysaccharide, preferably a phosphorylated polysaccharide as an active ingredient. Examples of phosphorylated polysaccharides include cultures of lactic acid bacteria that produce polysaccharides, polysaccharides purified from the cultures, polysaccharides obtained by phosphorylating polysaccharides chemically or enzymatically, and the like. The phosphorus content in the phosphorylated polysaccharide is preferably 0.01% or more, and more preferably 0.1% or more. In addition, the polysaccharide referred to in the present invention includes an oligosaccharide obtained by chemically or enzymatically degrading the polysaccharide.
The lactic acid bacteria used in the present invention are not limited as long as they are lactic acid bacteria producing polysaccharides. Acidic polysaccharides may be used alone or in combination of two or more different types.
As lactic acid bacteria, Lactobacillus bulgaricus, Lactococcus lactis ssp. Cremoris, etc. are used alone or in combination. Among these, Lactococcus lactis ssp. Cremoris KVS20 strain (Kitazawa H, Yamaguchi T, Miura M, Saito T, Itoh T, J Dairy Sci, 76, 1514-9 (1993)), Lactobacillus bulgaricus OLL1073R-1 strain (FERM P-17227 ) Is preferred.

多糖類を培養物そのままを用いても構わないが、特開2000-247895号公報記載の方法で中性多糖類を除く、または、必要に応じて下記の様にして精製したものを用いても構わない。尚、下記の工程の一部を省略、追加しても構わない。
1、遠心分離による培養物からの菌体の除去
2、エタノール沈殿によって高分子量の多糖類、タンパク質を沈殿として回収
3、タンパク質の除去
a)final 5-10%程度のトリクロロ酢酸でタンパク沈殿、遠心
b)boilすることによりタンパク質を熱変性、遠心
c)b)のあとにプロテイナーゼによるタンパク分解、あるいはDNAaseによる核酸の分解処理等も行い、透析
4、陰イオン交換樹脂による酸性多糖体類の吸着と溶出による回収
5、ゲルろ過により分子量100万以上の物質として酸性多糖体を精製する。
この時、酸性かつ分子量が近いタンパク質が混合していた場合は、ゲルろ過の前、あるいは後に何らかのタンパク除去操作を加えることも可能である。
The culture may be used as it is, but the neutral polysaccharide may be removed by the method described in JP-A-2000-247895, or a product purified as described below may be used if necessary. I do not care. Note that some of the following steps may be omitted or added.
1. Removal of bacterial cells from the culture by centrifugation 2. Recovery of high molecular weight polysaccharides and proteins as precipitates by ethanol precipitation 3. Removal of proteins
a) Protein precipitation with about 5-10% final trichloroacetic acid, centrifugation
b) Heat denaturation and centrifugation of the protein by boiling
c) After b), protein degradation by proteinase or nucleic acid degradation by DNAase is also performed, dialysis 4, recovery by adsorption and elution of acidic polysaccharides by anion exchange resin, and molecular weight of 1 million or more by gel filtration. Acidic polysaccharides are purified as a substance.
At this time, if proteins with acidic and close molecular weight are mixed, it is possible to add some protein removal operation before or after gel filtration.

酸性多糖類を製剤化して医薬品とする場合には、治療目的や投与経路等に応じて剤型を選択することができ、例えば、錠剤、丸剤、散剤、液剤、懸濁剤、乳剤、顆粒剤、カプセル剤、注射剤、坐剤、シロップ剤、浸剤、煎剤、チンキ剤等が挙げられる。また、製剤化のために、必要に応じて充填剤、増量剤、結合剤、保湿剤、崩壊剤、界面活性剤、滑沢剤等の希釈剤あるいは賦形剤を用いることができる。また、この医薬製剤中に着色剤、保存剤、香料、風味剤、甘味剤等や他の医薬品を医薬製剤中に含有させてもよい。   When an acidic polysaccharide is formulated into a pharmaceutical product, the dosage form can be selected according to the therapeutic purpose, administration route, etc., for example, tablets, pills, powders, solutions, suspensions, emulsions, granules Agents, capsules, injections, suppositories, syrups, soaking agents, decoction, tinctures and the like. For formulation, diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants, lubricants and the like can be used as necessary. In addition, a colorant, a preservative, a fragrance, a flavoring agent, a sweetening agent, and other pharmaceuticals may be included in the pharmaceutical preparation.

酸性多糖類を含む食品の形態としては、ヨーグルトの様な発酵乳、飲料等を挙げることができ、健康食品、特定保健用食品、栄養補助食品もしくはNK細胞活性化作用を表示した食品等として使用できる。酸性多糖類と食品衛生上許容できる配合物、例えば、安定化剤、保存料、着色料、香料、ビタミン等の配合物を上記リン酸化多糖類に適宜添加し、混合し、定法により、錠剤、粒状、顆粒状、粉末状、カプセル状、液状、ゼリー状、クリーム状、飲料等の食品とすることが出来る。
このような形態の、NK細胞活性化補助食品を摂取することにより、NK細胞活性化が図られるため、本発明で得られる食品は、インフルエンザなどの感染予防、癌の予防、進行の防止などに寄与することが可能である。
Examples of foods containing acidic polysaccharides include fermented milk and beverages such as yogurt, and can be used as health foods, foods for specified health use, dietary supplements, foods displaying NK cell activation, etc. it can. Acidic polysaccharides and food hygiene acceptable formulations, for example, stabilizers, preservatives, coloring agents, fragrances, vitamins and the like are added to the phosphorylated polysaccharides as appropriate, mixed, and tableted in a conventional manner. Granules, granules, powders, capsules, liquids, jellies, creams, beverages and other foods can be used.
Since NK cell activation is achieved by ingesting NK cell activation supplements in this form, the food obtained in the present invention can be used to prevent infection such as influenza, cancer, and progression. It is possible to contribute.

以下、本発明を説明するが、本発明がこの実施例に限定されないことはいうまでもない。   Hereinafter, the present invention will be described, but it goes without saying that the present invention is not limited to these examples.

乳酸菌由来多糖の製造
1、乳酸菌の培養
10%乳清をプロテアーゼで55℃、8時間処理した後酵母エキスを0.5%添加、pH7.0に調製したものにLactobacillus bulgaricusOLL1073R-1株(FERM P-17227)を接種し、37℃、24時間の静置培養を行った。
2、多糖の精製
10-20Lの培養液より菌体を遠心分離(22800 x g,4℃,20min)した後、エタノール沈殿(60-70%(v/v))を2回行った。沈殿物はMilliQ水に溶解し、トリクロロ酢酸(final 10%)によるタンパク変性、遠心分離(22800 x g,4℃,20min)による不溶物の除去を行った。
MilliQ水に対する透析、凍結乾燥を行った後、0.02M Tris-HCl(pH8.6)に溶解し、陰イオン交換樹脂であるDEAE-Sepharose(Amersham Biosciences)を用いて中性多糖と酸性多糖の分離を行った(図1)。中性多糖はPass画分として回収し、酸性多糖はNaClを用いて0-0.5Mイオン強度勾配による溶出で回収した。
回収された酸性多糖はSephacryl S-400HR(Amersham Biosciences)を用いてゲルろ過を行い、分子量による分離を行った。本多糖は分子量1×106Da以上の画分と分子量がより小さい画分に分離され、分子量1×106Da以上の画分について分取した(図2)。
分取した多糖はMilliQ水に対して透析後、凍結乾燥し、酸性多糖精製品を得た。
なお、多糖はグルコースを標準物質としてフェノール・硫酸法を用いて検出・定量した。
また、文献記載(Uemura J, Milchwissenschaft,53(8),443-6(1998))の方法で当該多糖を分析したところ、リン酸化多糖を含有していることが確認された。
Production of polysaccharides derived from lactic acid bacteria 1, cultivation of lactic acid bacteria
10% whey was treated with protease at 55 ° C for 8 hours, 0.5% yeast extract was added, and the pH adjusted to 7.0 was inoculated with Lactobacillus bulgaricus OLL1073R-1 strain (FERM P-17227) at 37 ° C for 24 hours Was statically cultured.
2. Purification of polysaccharides
Bacterial cells were centrifuged (22800 × g, 4 ° C., 20 min) from 10-20 L of the culture solution, and then ethanol precipitation (60-70% (v / v)) was performed twice. The precipitate was dissolved in MilliQ water, and protein denaturation with trichloroacetic acid (final 10%) and insoluble matter were removed by centrifugation (22800 xg, 4 ° C, 20 min).
After dialysis against MilliQ water and freeze-drying, dissolve in 0.02M Tris-HCl (pH 8.6) and separate neutral and acidic polysaccharides using DEAE-Sepharose (Amersham Biosciences), an anion exchange resin (FIG. 1). Neutral polysaccharides were collected as the Pass fraction, and acidic polysaccharides were collected by elution with 0-0.5M ionic strength gradient using NaCl.
The collected acidic polysaccharide was subjected to gel filtration using Sephacryl S-400HR (Amersham Biosciences) and separated by molecular weight. Honda sugar molecular weight 1 × 10 6 Da or more fractions and the molecular weight are separated into smaller fractions were collected for partial molecular weight 1 × 10 6 Da or more fractions (Figure 2).
The collected polysaccharide was dialyzed against MilliQ water and freeze-dried to obtain a purified acidic polysaccharide product.
The polysaccharide was detected and quantified using the phenol / sulfuric acid method with glucose as a standard substance.
Further, when the polysaccharide was analyzed by the method described in the literature (Uemura J, Milchwissenschaft, 53 (8), 443-6 (1998)), it was confirmed that it contained a phosphorylated polysaccharide.

多糖のNK活性
1、多糖のマウスへの経口投与試験
マウスBALB/c(雄、8週齢、SLC社)30匹を1群10匹で3群に分け、以下の投与物を3週間、ゾンデにより強制経口投与を行った。
1)蒸留水投与群:0.5ml/body/day
2) 実施例1で得た酸性多糖投与群:5mg/kg/day
3) 実施例1で得た酸性多糖投与群:30mg/kg/day
多糖は各濃度で蒸留水に溶解し、0.5ml/body/dayで投与を行った。
2、NK活性測定
3週間の投与終了後、個々のマウスよりそれぞれ脾臓を取り出し、細胞をRPMI1640(10%FCS)に懸濁することにより脾臓細胞懸濁液(1×107cells/ml)を調製した。
この脾臓細胞をエフェクター細胞、YAC-1細胞をターゲット細胞としてNK活性をfluorescence activated cell sorter(以下FACSとする)を用いて測定した。ターゲット細胞であるYAC-1は3,3’-dioctadecyloxacarbocyanine perchlorate(以下Dioとする)により蛍光染色した後、脾臓細胞とともに96穴マイクロプレート(丸底)を用いて37℃、5%CO2条件下で4時間培養を行った。培養終了前にPropidium Iodide(以下PIとする)を培養液に加え、死細胞を染色した。培養終了後、Johannの論文を参考にFACSを用いてDio、PIともに染色された細胞を死滅したYAC-1細胞として検出した(Johann S, Blumel G, Lipp M, Forster R,J Immunol Methods,185(2),209-16(1995))。なお、エフェクター細胞とターゲット細胞の比率は40:1とした。
その結果、酸性多糖30mg/kg/day投与群の脾臓細胞NK活性はコントロールである水投与群に比べ有意に高かった(P<0.01)。また、酸性多糖5mg/kg/day投与群においてもコントロールに比べ高い傾向(P<0.1)が見られた(図3)。
NK activity of polysaccharide 1 and oral administration test of polysaccharide to mice 30 mice BALB / c (male, 8 weeks old, SLC) were divided into 3 groups with 10 mice per group, and the following administration was administered for 3 weeks Was administered by oral gavage.
1) Distilled water administration group: 0.5ml / body / day
2) Acid polysaccharide administration group obtained in Example 1: 5 mg / kg / day
3) Acid polysaccharide administration group obtained in Example 1: 30 mg / kg / day
The polysaccharide was dissolved in distilled water at each concentration and administered at 0.5 ml / body / day.
2. Measurement of NK activity After 3 weeks of administration, remove the spleen from each mouse and suspend the cells in RPMI1640 (10% FCS) to obtain a spleen cell suspension (1 × 10 7 cells / ml). Prepared.
NK activity was measured using a fluorescence activated cell sorter (hereinafter referred to as FACS) using the spleen cells as effector cells and YAC-1 cells as target cells. The target cell, YAC-1, was fluorescently stained with 3,3'-dioctadecyloxacarbocyanine perchlorate (hereinafter referred to as Dio), and then used together with spleen cells in a 96-well microplate (round bottom) at 37 ° C and 5% CO 2 Incubated for 4 hours. Before completion of the culture, Propidium Iodide (hereinafter referred to as PI) was added to the culture solution to stain dead cells. After completion of the culture, cells stained with Dio and PI were detected as dead YAC-1 cells using FACS with reference to Johann's paper (Johann S, Blumel G, Lipp M, Forster R, J Immunol Methods, 185 (2), 209-16 (1995)). The ratio of effector cells to target cells was 40: 1.
As a result, the spleen cell NK activity in the acidic polysaccharide 30 mg / kg / day administration group was significantly higher than that in the control water administration group (P <0.01). In addition, the acidic polysaccharide 5 mg / kg / day administration group showed a higher tendency (P <0.1) than the control (FIG. 3).

多糖産生乳酸菌を利用した発酵乳の作製
NK活性上昇作用を有する酸性多糖体を産生するL. bulgaricus OLL1073R-1を用いて発酵乳を作製した。生乳、脱脂粉乳、砂糖を使用し、SNF9.7%、FAT3.05%、砂糖3.0%に調製した溶液(以下発酵乳Mix)にL. bulgaricus OLL1073R-1、S. thermophilus OLS3059(FERM P-15487)をスターター菌として加え、43℃で発酵を行った。酸度0.7で発酵を終了し、4℃で1日保存することで最終酸度0.78となった。また、対照発酵乳としてL. bulgaricus OLL1256及びS. thermophilus OLS3295をスターター菌として用いた発酵乳についても作製した。
Preparation of fermented milk using polysaccharide-producing lactic acid bacteria Fermented milk was prepared using L. bulgaricus OLL1073R-1 which produces an acidic polysaccharide having an NK activity increasing action. Using raw milk, skim milk powder and sugar, a solution prepared to SNF9.7%, FAT3.05%, sugar 3.0% (hereinafter fermented milk Mix) was added to L. bulgaricus OLL1073R-1, S. thermophilus OLS3059 (FERM P-15487 ) As a starter fungus and fermented at 43 ° C. Fermentation was completed at an acidity of 0.7, and a final acidity of 0.78 was obtained by storing at 4 ° C for 1 day. In addition, fermented milk using L. bulgaricus OLL1256 and S. thermophilus OLS3295 as starter fungi as control fermented milk was also produced.

多糖産生乳酸菌を利用した発酵乳のNK活性
1、多糖産生乳酸菌を利用した発酵乳のマウスへの経口投与試験
マウスBALB/c(雄、11週齢、SLC社)32匹を1群8匹で4群に分け、以下の投与物を4週間、ゾンデにより強制経口投与を行った。
1) 蒸留水投与群 1.0ml/body/day
2) L. bulgaricus OLL1073R-1発酵乳(実施例3)投与群 200mg/body/day
3) 対照発酵乳(実施例3)投与群 200mg/body/day
4) 発酵乳Mix(実施例3)投与群 200mg/body/day
発酵乳、発酵乳Mixは凍結乾燥物を用い、投与時に200mg/mlで蒸留水に懸濁した。
2、NK活性測定
4週間の投与終了後、個々のマウスよりそれぞれ脾臓を取り出し、細胞をRPMI1640(10%FCS)に懸濁することにより脾臓細胞懸濁液(1×107cells/ml)を調製した。
この脾臓細胞をエフェクター細胞、YAC-1細胞をターゲット細胞としてNK活性をfluorescence activated cell sorter(以下FACSとする)を用いて測定した。ターゲット細胞であるYAC-1は3,3’-dioctadecyloxacarbocyanine perchlorate(以下Dioとする)により蛍光染色した後、脾臓細胞とともに96穴マイクロプレート(丸底)を用いて37℃、5%CO2条件下で4時間培養を行った。培養終了前にPropidium Iodide(以下PIとする)を培養液に加え、死細胞を染色した。培養終了後、Johannの論文を参考にFACSを用いてDio、PIともに染色された細胞を死滅したYAC-1細胞として検出した(Johann S, Blumel G, Lipp M, Forster R,J Immunol Methods,185(2),209-16(1995))。なお、エフェクター細胞とターゲット細胞の比率は40:1とした。
その結果、発酵乳投与では多糖体産生菌であるL. bulgaricus OLL1073R-1を使用した発酵乳投与群においてNK活性がコントロールである蒸留水投与群に比べ有意に高く(p<0.05)、発酵乳Mixと対照発酵乳に対しては高い傾向(p<0.1)が見られた(図4)。

NK activity of fermented milk using polysaccharide-producing lactic acid bacteria 1. Oral administration test of fermented milk using polysaccharide-producing lactic acid bacteria to mice 32 mice BALB / c (male, 11 weeks old, SLC) with 8 mice per group Divided into 4 groups, the following doses were administered by oral gavage with a sonde for 4 weeks.
1) Distilled water administration group 1.0ml / body / day
2) L. bulgaricus OLL1073R-1 fermented milk (Example 3) administration group 200 mg / body / day
3) Control fermented milk (Example 3) administration group 200 mg / body / day
4) Fermented milk mix (Example 3) administration group 200mg / body / day
Fermented milk and fermented milk Mix were lyophilized and suspended in distilled water at 200 mg / ml at the time of administration.
2. Measurement of NK activity After 4 weeks of administration, remove the spleen from each mouse and suspend the cells in RPMI1640 (10% FCS) to obtain a spleen cell suspension (1 × 10 7 cells / ml). Prepared.
NK activity was measured using a fluorescence activated cell sorter (hereinafter referred to as FACS) using the spleen cells as effector cells and YAC-1 cells as target cells. The target cell, YAC-1, was fluorescently stained with 3,3'-dioctadecyloxacarbocyanine perchlorate (hereinafter referred to as Dio), and then used together with spleen cells in a 96-well microplate (round bottom) at 37 ° C and 5% CO 2 Incubated for 4 hours. Before completion of the culture, Propidium Iodide (hereinafter referred to as PI) was added to the culture solution to stain dead cells. After completion of the culture, cells stained with Dio and PI were detected as dead YAC-1 cells using FACS with reference to Johann's paper (Johann S, Blumel G, Lipp M, Forster R, J Immunol Methods, 185 (2), 209-16 (1995)). The ratio of effector cells to target cells was 40: 1.
As a result, fermented milk administration showed significantly higher NK activity in the fermented milk administration group using L. bulgaricus OLL1073R-1 (p <0.05) compared to the distilled water administration group, which was a control, using fermented milk. A high tendency (p <0.1) was observed for Mix and control fermented milk (FIG. 4).
.

本発明によれば、NK細胞活性化効果が高いので、免疫賦活剤として有用であるだけでなく、免疫賦活用飲食品としても利用することができる。   According to the present invention, since the NK cell activation effect is high, it is not only useful as an immunostimulator, but can also be used as an immunostimulatory food or drink.

陰イオン交換樹脂 DEAE sepharoseによる中性多糖と酸性多糖の分離を示す図である。It is a figure which shows isolation | separation of neutral polysaccharide and acidic polysaccharide by anion exchange resin DEAE sepharose. 酸性多糖のSephacryl S-400HRを用いたゲルろ過による分離を示す図である。It is a figure which shows isolation | separation by gel filtration using Sephacryl S-400HR of acidic polysaccharide. 酸性多糖を3週間経口投与したマウスにおける脾臓細胞のNK活性を示す図である。(検定方法:Student's t-test)It is a figure which shows NK activity of the spleen cell in the mouse | mouth which orally administered acidic polysaccharide for 3 weeks. (Test method: Student's t-test) 多糖産生乳酸菌を利用した発酵乳を4週間経口投与したマウスにおける脾臓細胞のNK活性を示す図である。(検定方法:Student's t-test)It is a figure which shows the NK activity of a spleen cell in the mouse | mouth which orally administered fermented milk using a polysaccharide-producing lactic acid bacterium for 4 weeks. (Test method: Student's t-test)

Claims (6)

L. bulgaricus OLL1073R-1およびS. thermophilus OLS3059をスターター菌として製造する、NK細胞活性化作用を有する発酵乳。 A fermented milk having an NK cell activation effect, which produces L. bulgaricus OLL1073R-1 and S. thermophilus OLS3059 as a starter fungus. 酸性多糖類をNK細胞活性化に有効な量含有する、請求項に記載の発酵乳。 The fermented milk according to claim 1 , comprising an acidic polysaccharide in an amount effective for NK cell activation. 酸性多糖類がリン酸化多糖類である、請求項に記載の発酵乳。 Fermented milk according to claim 2 , wherein the acidic polysaccharide is a phosphorylated polysaccharide. リン酸化多糖類のリン含有量が0.01%以上である、請求項に記載の発酵乳。 The fermented milk of Claim 3 whose phosphorus content of a phosphorylated polysaccharide is 0.01% or more. 前記請求項1〜に記載の発酵乳を有効成分とするNK細胞活性化剤。 The NK cell activator which uses the fermented milk of the said Claims 1-4 as an active ingredient. 乳清、生乳および/または脱脂粉乳を含有する溶液に、L. bulgaricus OLL1073R-1およびS. thermophilus OLS3059を添加することを含む、NK細胞活性化作用を有する酸性多糖類を製造する方法。   A method for producing an acidic polysaccharide having NK cell activation action, comprising adding L. bulgaricus OLL1073R-1 and S. thermophilus OLS3059 to a solution containing whey, raw milk and / or skim milk powder.
JP2004203601A 2003-12-12 2004-07-09 NK cell activator Expired - Lifetime JP5177728B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004203601A JP5177728B2 (en) 2003-12-12 2004-07-09 NK cell activator

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003414258 2003-12-12
JP2003414258 2003-12-12
JP2004203601A JP5177728B2 (en) 2003-12-12 2004-07-09 NK cell activator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010230889A Division JP5744462B2 (en) 2003-12-12 2010-10-13 NK cell activator

Publications (2)

Publication Number Publication Date
JP2005194259A JP2005194259A (en) 2005-07-21
JP5177728B2 true JP5177728B2 (en) 2013-04-10

Family

ID=34829064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004203601A Expired - Lifetime JP5177728B2 (en) 2003-12-12 2004-07-09 NK cell activator

Country Status (1)

Country Link
JP (1) JP5177728B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015029967A1 (en) 2013-08-26 2015-03-05 株式会社明治 Antibody titer-increasing agent using lactic acid bacterium

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5744462B2 (en) * 2003-12-12 2015-07-08 株式会社明治 NK cell activator
WO2008147445A2 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
CA2673714A1 (en) * 2006-12-26 2008-07-03 Meiji Dairies Corporation Fermented milk for skin improvement and/or treatment and process for producing the same
SG10201407677WA (en) * 2009-11-25 2015-01-29 Meiji Co Ltd Antiviral agent and food/beverage composition
JP6016326B2 (en) * 2009-12-09 2016-10-26 株式会社明治 Screening method for lactic acid bacteria
CN103179975B (en) 2010-08-31 2015-07-15 国立大学法人新潟大学 Intestine immunomodulator
ES2668096T3 (en) * 2010-12-28 2018-05-16 Kirin Holdings Kabushiki Kaisha Use of Lactococcus bacteria in the treatment or prevention of viral infections
CN104780767B (en) * 2012-11-29 2018-07-06 株式会社明治 Yoghourt and its manufacturing method, the manufacturing method of lactic acid bacteria vitro functional product and lactic acid bacteria vitro functional product increasing agent
WO2017183595A1 (en) * 2016-04-20 2017-10-26 株式会社 明治 Fermented milk for ameliorating feeling of fatigue
WO2018112366A1 (en) 2016-12-15 2018-06-21 The Regents Of The University Of California Oral composition comprising lactic acid bacteria for regulating immune responses and methods related thereto
CN112334141B (en) * 2018-06-14 2024-12-13 株式会社明治 Compositions for promoting immune checkpoint inhibition therapy
JP7369992B2 (en) * 2019-05-13 2023-10-27 株式会社明治 Fermented milk for improving autonomic nervous function
TW202229319A (en) * 2020-10-12 2022-08-01 日商明治股份有限公司 Protein having effect of improving immunostimulatory activity of lactic acid bacteria exopolysaccharide, and fermented milk including same and method for producing same
WO2023120547A1 (en) * 2021-12-22 2023-06-29 株式会社明治 Composition for preventing secondary sexually transmitted diseases or reducing the risk of developing same
JPWO2023204234A1 (en) 2022-04-20 2023-10-26

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3530674B2 (en) * 1996-03-04 2004-05-24 明治乳業株式会社 Mutagenic substance absorption inhibitory food
JP3017493B1 (en) * 1999-02-25 2000-03-06 明治乳業株式会社 Autoimmune disease prevention composition
JP3784045B2 (en) * 2000-04-27 2006-06-07 明治乳業株式会社 LDL oxidation-suppressing food and drink and pharmaceuticals

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015029967A1 (en) 2013-08-26 2015-03-05 株式会社明治 Antibody titer-increasing agent using lactic acid bacterium
US10195271B2 (en) 2013-08-26 2019-02-05 Meiji Co., Ltd. Antibody titer-increasing agent using lactic acid bacterium

Also Published As

Publication number Publication date
JP2005194259A (en) 2005-07-21

Similar Documents

Publication Publication Date Title
JP5177728B2 (en) NK cell activator
AU2011275573B2 (en) Macromolecular complex of bacterial origin and use of said macromolecular complex for preventing and treating inflammatory rheumatism
Makino et al. Immunomodulatory effects of polysaccharides produced by Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1
JP5031249B2 (en) Bacteria-containing composition having anti-inflammatory effect
ES2662844T3 (en) Generation of mutant strain producing only PSA
AU2017438436B2 (en) Muscle-building composition
US10548916B2 (en) Composition comprising neoagarooligosaccharide as active ingredient, for prevention or treatment of sepsis or septic shock
JP2017014231A (en) NK cell activator
CN112351693A (en) Anti-influenza virus agent for inhibiting severe influenza
JP5916288B2 (en) Process for producing innate immunity activator with enhanced innate immunity promoting action and royal jelly-derived innate immunity activator produced by the process
JP2018035102A (en) Anti-obesity agent
JP2015070855A (en) Fermented milk production method and antiviral agent production method
JP3174611B2 (en) Immunostimulating composition
JP2005220065A (en) Immunopotentiator
JP3995733B2 (en) Immunostimulatory composition
TWI568368B (en) Lactobacillus paracasei K71
JP5502449B2 (en) Intestinal flora balance improving agent and method for producing the same
BR122022016606B1 (en) LACTOBACILLUS PARACASEI DEAD BY HEATING, DRUG, FOOD OR DRINK, FEED, AGENT PROMOTING IL-12 PRODUCTION AND USE
JP6016326B2 (en) Screening method for lactic acid bacteria
US20200316141A1 (en) Composition To Support Healthy Brain Function
JP4689060B2 (en) Immunostimulatory composition
JP2024046233A (en) Composition for improving intestinal barrier
JPH0859500A (en) Peptide mixture that prevents intestinal bacteria from entering the body, and composition containing the peptide mixture
KR20160037879A (en) Carrier for transporting substance to macrophages
WO2023120547A1 (en) Composition for preventing secondary sexually transmitted diseases or reducing the risk of developing same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070705

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20091022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091130

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20091207

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20091116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100528

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100602

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101013

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101228

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121228

R150 Certificate of patent or registration of utility model

Ref document number: 5177728

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

EXPY Cancellation because of completion of term